Allosteric modulators of rhodopsin-like G protein-coupled receptors: Opportunities in drug development

Pharmacology and Therapeutics

Volumn 135, Issue 3, 2012, Pages 292-315

  Müller, Christa E ^a   Schiedel, Anke C ^a   Baqi, Younis ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Ago allosteric modulators; Allosteric agonists; Biased signaling; Negative allosteric modulators; Positive allosteric modulators

Indexed keywords

2 (2 PYRIDYL)ISATOGEN; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR AFFECTING AGENT; BETA ARRESTIN; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CINACALCET; CLOPIDOGREL; FURAN 1; G PROTEIN COUPLED RECEPTOR; GONADORELIN AGONIST; LUF 6000; MARAVIROC; MK 577; ML 159; MONTELUKAST; MUSCARINIC M1 RECEPTOR; ORG 27569; PLERIXAFOR; PRANLUKAST; PRASUGREL; RHODOPSIN LIKE G PROTEIN COUPLED RECEPTOR; RIMONABANT; RTI 371; SALICYLIC ACID; TANGERETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VU 0029757; VU 0090157; VU 0405652; VU 10010;

ALLOSTERISM; ARTICLE; DEPRESSION; DRUG RECEPTOR BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; IC 50; OBESITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; STEM CELL MOBILIZATION; STOICHIOMETRY; SUICIDE;

EID: 84864462348     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.06.002     Document Type: Review

References (185)

1. A. Adunsky, J. Chandler, N. Heyden, J. Lutkiewicz, B.B. Scott, and Y. Berd MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study Arch Gerontol Geriatr 53 2011 183 189
2. i-independent ERK1/2 activation J Biol Chem 287 2012 12070 12082
3. I. Algaier, J.A. Jakubowski, F. Asai, and I. von Kügelgen Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor J Thromb Haemost 6 2008 1908 1914
4. M. Allegretti, R. Bertini, M.C. Cesta, C. Bizzarri, R. Di Bitondo, and V. Di Cioccio 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors J Med Chem 48 2005 4312 4331
5. L. Alvarez-Jaimes, S.W. Sutton, D. Nepomuceno, S.T. Motley, M. Cik, and E. Stocking In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependency PLoS One 7 2012 e30792
6. J. Antony, K. Kellershohn, M. Mohr-Andrä, A. Kebig, S. Prilla, and M. Muth Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J 23 2009 442 450
7. 1 adenosine receptor allosteric modulators and antagonists Bioorg Med Chem 17 2009 7353 7361
8. 1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3- benzoylthiophenes J Med Chem 52 2009 4543 4547
9. V. Avlani, L.T. May, P.M. Sexton, and A. Christopoulos Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors J Pharmacol Exp Ther 308 2004 1062 1072
10. J. Ballesteros, and J. Ransom In-target versus off-target allosteric modulators of GPCRs Drug Discov Today Ther Strateg 3 2006 445 450
11. J. Ballesteros, and H. Weinstein Integrated methods for the construction of three-dimensional models of structure-function relations in G protein-coupled receptors Methods Neurosci 25 1995 366 428
12. 1-adenosine receptor Bioorg Med Chem Lett 10 2000 1953 1957
13. 1 adenosine receptor J Med Chem 46 2003 794 809
14. 1 allosteric enhancer Bioorg Med Chem Lett 16 2006 1402 1404
15. 1 adenosine receptor Mini Rev Med Chem 7 2007 559 569
16. R. Bertini, M. Allegretti, C. Bizzarri, A. Moriconi, M. Locati, and G. Zampella Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury Proc Natl Acad Sci U S A 101 2004 11791 11796
17. N.J. Birdsall Class A GPCR heterodimers: evidence from binding studies Trends Pharmacol Sci 31 2010 499 508
18. J.S. Blakeney, R.C. Reid, G.T. Le, and D.P. Fairlie Nonpeptidic ligands for peptide-activated G protein-coupled receptors Chem Rev 107 2007 2960 3041
19. V. Blandin, P. Vigne, J.P. Breittmayer, and C. Frelin Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid Mol Pharmacol 58 2000 1461 1469
20. 4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats J Pharmacol Exp Ther 327 2008 941 953
21. T.M. Bridges, and C.W. Lindsley G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms ACS Chem Biol 3 2008 530 541
22. 1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties Bioorg Med Chem Lett 18 2008 5439 5442
23. 1 receptor binding and function by 2-amino-3-benzoylthiophenes Mol Pharmacol 38 1990 939 949
24. 1 receptor binding by 2-amino-3-benzoylthiophenes Mol Pharmacol 38 1990 950 958
25. A. Brunschweiger, and C.E. Müller P2 receptors activated by uracil nucleotides - an update Curr Med Chem 13 2006 289 312
26. N.T. Burford, J. Watson, R. Bertekap, and A. Alt Strategies for the identification of allosteric modulators of G-protein-coupled receptors Biochem Pharmacol 81 2011 691 702
27. M. Canals, P.M. Sexton, and A. Christopoulos Allostery in GPCRs: 'MWC' revisited Trends Biochem Sci 36 2011 663 672
28. M. Canals, J.R. Lane, A. Wen, P.J. Scammells, P.M. Sexton, and A. Christopoulos A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation J Biol Chem 287 2012 650 659
29. M. Cattaneo ADP receptors: inhibitory strategies for antiplatelet therapy Drug News Perspect 19 2006 253 259
30. D.T. Chalmers, and D.P. Behan The use of constitutively active GPCRs in drug discovery and functional genomics Nat Rev Drug Discov 1 2002 599 608
31. 4 receptor as an approach to treating schizophrenia Proc Natl Acad Sci U S A 105 2008 10978 10983
32. J.P. Changeux Allostery and the Monod-Wyman-Changeux model after 50 years Annu Rev Biophys 31 2011
33. 3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches Med Res Rev 2011 10.1002/ med.20254
34. 1 adenosine receptor agonist allosteric enhancers having improved potency J Med Chem 48 2005 5131 5139
35. A. Christopoulos, and T. Kenakin G protein-coupled receptor allosterism and complexing Pharmacol Rev 54 2002 323 374
36. A. Christopoulos, L.T. May, V.A. Avlani, and P.M. Sexton G-protein-coupled receptor allosterism: the promise and the problem(s) Biochem Soc Trans 32 2004 873 877
37. M. Congreve, and F. Marshall The impact of GPCR structures on pharmacology and structure-based drug design Br J Pharmacol 159 2010 986 996
38. P.J. Conn, A. Christopoulos, and C.W. Lindsley Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat Rev Drug Discov 8 2009 41 54
39. P.J. Conn, C.K. Jones, and C.W. Lindsley Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol Sci 30 2009 148 155
40. P.J. Conn, C.W. Lindsley, and C.K. Jones Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol Sci 30 2009 25 31
41. L. Cosyn, S. Van Calenbergh, B.V. Joshi, H. Ko, R.L. Carter, and K.T. Harden Synthesis and P2Y receptor activity of nucleoside 5′-phosphonate derivatives Bioorg Med Chem Lett 19 2009 3002 3005
42. 1 receptors J Med Chem 55 2012 2125 2143
43. A.P. Davenport International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature Pharmacol Rev 54 2002 219 226
44. M. De Amici, C. Dallanoce, U. Holzgrabe, C. Tränkle, and K. Mohr Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities Med Res Rev 30 2010 463 549
45. J.G. De Mey, M.G. Compeer, P. Lemkens, and M.J. Meens ETA-receptor antagonists or allosteric modulators? Trends Pharmacol Sci 32 2011 345 351
46. G.J. Digby, P.J. Conn, and C.W. Lindsley Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs Curr Opin Drug Discov Devel 13 2010 587 594
47. T. Disingrini, M. Muth, C. Dallanoce, E. Barocelli, S. Bertoni, and K. Kellershohn Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors J Med Chem 49 2006 366 372
48. L. Dowal, D.S. Sim, J.R. Dilks, P. Blair, S. Beaudry, and B.M. Denker Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1 Proc Natl Acad Sci U S A 108 2011 2951 2956
49. P.W. Elsinghorst, W. Hartig, D. Gündisch, K. Mohr, C. Tränkle, and M. Gütschow A hydrazide linker strategy for heterobivalent compounds as ortho- and allosteric ligands of acetylcholine-binding proteins Curr Top Med Chem 11 2011 2731 2748
50. 6 receptors J Med Chem 54 2011 2878 2890
51. 1 receptor allosteric modulators and antagonists J Med Chem 51 2008 6165 6172
52. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, J. Linden, and C.E. Müller International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update Pharmacol Rev 63 2011 1 34
53. K. Fuxe, D. Marcellino, D.O. Borroto-Escuela, M. Frankowska, L. Ferraro, and D. Guidolin The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions J Recept Signal Transduct Res 30 2010 272 283
54. K. Fuxe, D.O. Borroto-Escuela, D. Marcellino, W. Romero-Fernandez, M. Frankowska, and D. Guidolin GPCR heteromers and their allosteric receptor-receptor interactions Curr Med Chem 19 2012 356 363
55. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives Mol Pharmacol 60 2001 1057 1063
56. Z.G. Gao, S.K. Kim, A.S. Gross, A. Chen, J.B. Blaustein, and K.A. Jacobson Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor Mol Pharmacol 63 2003 1021 1031
57. 3 adenosine receptors Biochem Pharmacol 65 2003 525 534
58. 1 receptor signaling without affecting nucleotide binding Biochem Pharmacol 68 2004 231 237
59. Z.G. Gao, K. Ye, A. Goblyos, A.P. Ijzerman, and K.A. Jacobson Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000 BMC Pharmacol 8 2008 20
60. 3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers Biochem Pharmacol 82 2011 658 668
61. U. Gether Uncovering molecular mechanisms involved in activation of G protein-coupled receptors Endocr Rev 21 2000 90 113
62. 2A adenosine receptors Eur J Med Chem 43 2008 1639 1647
63. A. Göblyös, and A.P. IJzerman Allosteric modulation of adenosine receptors Purinergic Signal 5 2009 51 61
64. A. Göblyös, and A.P. IJzerman Allosteric modulation of adenosine receptors Biochim Biophys Acta 1808 2011 1309 1318
65. 3 adenosine receptor J Med Chem 49 2006 3354 3361
66. 2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias J Biol Chem 285 2010 7459 7474
67. H.G. Häcker, M.T. Sisay, and M. Gütschow Allosteric modulation of caspases Pharmacol Ther 132 2011 180 195
68. 2 muscarinic acetylcholine receptor bound to an antagonist Nature 482 2012 547 551 (LID)
69. R.A. Hall, and R.J. Lefkowitz Regulation of G protein-coupled receptor signaling by scaffold proteins Circ Res 91 2002 672 680
70. Y. Han, I.S. Moreira, E. Urizar, H. Weinstein, and J.A. Javitch Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation Nat Chem Biol 5 2009 688 695
71. M.A. Hanson, C.B. Roth, E. Jo, M.T. Griffith, F.L. Scott, and G. Reinhart Crystal structure of a lipid G protein-coupled receptor Science 335 2012 851 855
72. 35S]GTPgammaS binding assay: approaches and applications in pharmacology Life Sci 74 2003 489 508
73. P. Hauske, C. Ottmann, M. Meltzer, M. Ehrmann, and M. Kaiser Allosteric regulation of proteases Chembiochem 9 2008 2920 2928
74. L.H. Heitman, and A.P. IJzerman G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands Med Res Rev 28 2008 975 1011
75. 3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor Mol Pharmacol 73 2008 518 524
76. 3 receptor J Med Chem 52 2009 926 931
77. L.H. Heitman, R. Narlawar, H. de Vries, M.N. Willemsen, D. Wolfram, and J. Brussee Substituted terphenyl compounds as the first class of low molecular weight allosteric inhibitors of the luteinizing hormone receptor J Med Chem 52 2009 2036 2042
78. L.H. Heitman, G. Kleinau, J. Brussee, G. Krause, and A.P. IJzerman Determination of different putative allosteric binding pockets at the lutropin receptor by using diverse drug-like low molecular weight ligands Mol Cell Endocrinol 351 2012 326 336
79. A. Hendricson, M. Matchett, M. Ferrante, C. Ferrante, E. Hunnicutt, and R. Westphal Design of an automated enhanced-throughput platform for functional characterization of positive allosteric modulator-induced leftward shifts in apparent agonist potency in vitro J Lab Autom 17 2012 104 115
80. 2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling J Med Chem 52 2009 2762 2775
81. B. Holst, E. Brandt, A. Bach, A. Heding, and T.W. Schwartz Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling Mol Endocrinol 19 2005 2400 2411
82. B. Holst, T.M. Frimurer, J. Mokrosinski, T. Halkjaer, K.B. Cullberg, and C.R. Underwood Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor Mol Pharmacol 75 2009 44 59
83. 2C receptor Mol Pharmacol 64 2003 78 84
84. A. Ivetac, and J.A. McCammon Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach Chem Biol Drug Des 76 2010 201 217
85. K.A. Jacobson, Z.G. Gao, A. Göblyös, and A.P. IJzerman Allosteric modulation of purine and pyrimidine receptors Adv Pharmacol 61 2011 187 220
86. J. Jakubik, E.E. El-Fakahany, and S. Tucek Evidence for a tandem two-site model of ligand binding to muscarinic acetylcholine receptors J Biol Chem 275 2000 18836 18844
87. J.M. Janz, Y. Ren, R. Looby, M.A. Kazmi, P. Sachdev, and A. Grunbeck Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4 J Am Chem Soc 133 2011 15878 15881
88. A.A. Jensen, and T.A. Spalding Allosteric modulation of G-protein coupled receptors Eur J Pharm Sci 21 2004 407 420
89. C. Jorand-Lebrun, B. Brondyk, J. Lin, S. Magar, R. Murray, and A. Reddy Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists Bioorg Med Chem Lett 17 2007 2080 2085
90. 2 receptor antagonists Drug Dev Res 59 2003 72 81
91. A. Kebig, E. Kostenis, K. Mohr, and M. Mohr-Andrä An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators J Recept Signal Transduct Res 29 2009 140 145
92. T. Kenakin Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs Curr Neuropharmacol 5 2007 149 156
93. T. Kenakin Overview of receptor interactions of agonists and antagonists Curr Protoc Pharmacol 2008 (Chapter 4, Unit 41)
94. T.P. Kenakin Biased signalling and allosteric machines: new vistas and challenges for drug discovery Br J Pharmacol 165 2012 1659 1669
95. P. Keov, P.M. Sexton, and A. Christopoulos Allosteric modulation of G protein-coupled receptors: a pharmacological perspective Neuropharmacology 60 2011 24 35
96. 3 adenosine receptor J Med Chem 52 2009 2098 2108
97. G. Kleinau, A.K. Haas, S. Neumann, C.L. Worth, I. Hoyer, and J. Furkert Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor FASEB J 24 2010 2347 2354
98. H. Kords, H. Lullmann, F.K. Ohnesorge, and O. Wassermann Action of atropine and some hexane-1,6-bis-ammonium derivatives upon the toxicity of DFP im mice Eur J Pharmacol 3 1968 341 346
99. 3 muscarinic acetylcholine receptor Nature 482 2012 552 556 (LID)
100. C. La Motta, S. Sartini, M. Morelli, S. Taliani, and F. Da Settimo Allosteric modulators for adenosine receptors: an alternative to the orthosteric ligands Curr Top Med Chem 10 2010 976 992
101. M.C. Lagerstrom, and H.B. Schiöth Structural diversity of G protein-coupled receptors and significance for drug discovery Nat Rev Drug Discov 7 2008 339 357
102. J.R. Lane, M.W. Beukers, T. Mulder-Krieger, and A.P. IJzerman The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor Biochem Pharmacol 79 2010 48 56
103. 1 muscarinic receptor agonist, 77-LH-28-1 Br J Pharmacol 154 2008 1104 1115
104. 1 muscarinic acetylcholine receptors Biochem Pharmacol 68 2004 2207 2219
105. T. Lee, R. Schwandner, G. Swaminath, J. Weiszmann, M. Cardozo, and J. Greenberg Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2 Mol Pharmacol 74 2008 1599 1609
106. R.A. Leppik, and N.J. Birdsall Agonist binding and function at the human alpha(2A)-adrenoceptor: allosteric modulation by amilorides Mol Pharmacol 58 2000 1091 1099
107. 1A-adrenergic receptor Mol Pharmacol 57 2000 436 445
108. 1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc Natl Acad Sci U S A 106 2009 15950 15955
109. E.L. Maillet, N. Pellegrini, C. Valant, B. Bucher, M. Hibert, and J.J. Bourguignon A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties FASEB J 21 2007 2124 2134
110. L. Mamedova, V. Capra, M.R. Accomazzo, Z.G. Gao, S. Ferrario, and M. Fumagalli CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors Biochem Pharmacol 71 2005 115 125
111. 1 muscarinic receptors reveals multiple modes of activity Mol Pharmacol 75 2009 577 588
112. 1 muscarinic receptor J Biol Chem 286 2011 31661 31675
113. L.T. May, and A. Christopoulos Allosteric modulators of G-protein-coupled receptors Curr Opin Pharmacol 3 2003 551 556
114. L.T. May, K. Leach, P.M. Sexton, and A. Christopoulos Allosteric modulation of G protein-coupled receptors Annu Rev Pharmacol Toxicol 47 2007 1 51
115. 3 receptor homodimers: quantification using single-cell ligand-binding kinetics FASEB J 25 2011 3465 3476
116. 1 allosteric agonist TBPB. Part II: amides, sulfonamides and ureas - the effect of capping the distal basic piperidine nitrogen Bioorg Med Chem Lett 18 2008 5443 5447
117. G. Milligan, and N.J. Smith Allosteric modulation of heterodimeric G-protein-coupled receptors Trends Pharmacol Sci 28 2007 615 620
118. G. Milligan, L.A. Stoddart, and N.J. Smith Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3 Br J Pharmacol 158 2009 146 153
119. 2 muscarinic allosteric modulators Receptors Channels 9 2003 229 240
120. K. Mohr, C. Tränkle, E. Kostenis, E. Barocelli, M. De Amici, and U. Holzgrabe Rational design of dualsteric GPCR ligands: quests and promise Br J Pharmacol 159 2010 997 1008
121. S. Moro, C. Hoffmann, and K.A. Jacobson Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor Biochemistry 38 1999 3498 3507
122. C.E. Müller, and K.A. Jacobson Recent developments in adenosine receptor ligands and their potential as novel drugs Biochim Biophys Acta 1808 2011 1290 1308
123. J. Nagamine, T. Kawamura, T. Tokunaga, W.E. Hume, R. Nagata, and T. Nakagawa Synthesis and pharmacological profile of an orally-active growth hormone secretagogue, SM-130686 Comb Chem High Throughput Screen 9 2006 187 196
124. 1 receptor J Med Chem 53 2010 3028 3037
125. H.A. Navarro, J.L. Howard, G.T. Pollard, and F.I. Carroll Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br J Pharmacol 156 2009 1178 1184
126. I. Navratilova, and A.L. Hopkins Emerging role of surface plasmon resonance in fragment-based drug diescovery Future Med Chem 3 2011 1809 1820
127. V. Nawaratne, K. Leach, C.C. Felder, P.M. Sexton, and A. Christopoulos Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms J Biol Chem 285 2010 19012 19021
128. S. Neumann, W. Huang, S. Titus, G. Krause, G. Kleinau, and A.T. Alberobello Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice Proc Natl Acad Sci U S A 106 2009 12471 12476
129. S. Neumann, E. Eliseeva, J.G. McCoy, G. Napolitano, C. Giuliani, and F. Monaco A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor J Clin Endocrinol Metab 96 2011 548 554
130. C.L. Newton, A.M. Whay, C.A. McArdle, M. Zhang, C.J. van Koppen, and R. van de Lagemaat Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist Proc Natl Acad Sci U S A 108 2011 7172 7176
131. G. Nikolakopoulos, H. Figler, J. Linden, and P.J. Scammells 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers Bioorg Med Chem 14 2006 2358 2365
132. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat Rev Drug Discov 5 2006 993 996
133. K. Patel, A. Barnes, J. Camacho, C. Paterson, R. Boughtflower, and D. Cousens Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells Eur J Pharmacol 430 2001 203 210
134. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, and M.R. Elphick International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev 62 2010 588 631
135. 1 receptor Mol Pharmacol 68 2005 1484 1495
136. P.R. Reid, T.M. Bridges, D.J. Sheffler, H.P. Cho, L.M. Lewis, and E. Days Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe Bioorg Med Chem Lett 21 2011 2697 2701
137. 1 adenosine receptor J Med Chem 51 2008 5875 5879
138. 1 adenosine receptors: state of the art and new horizons for drug development Curr Med Chem 17 2010 3488 3502
139. 1 receptor Br J Pharmacol 152 2007 565 566
140. M. Rossi, A. Dimida, E. Ferrarini, E. Silvano, G. De Marco, and P. Agretti Presence of a putative steroidal allosteric site on glycoprotein hormone receptors Eur J Pharmacol 623 2009 155 159
141. M.R. Sablone, M.C. Cesta, A. Moriconi, A. Aramini, C. Bizzarri, and C. Di Giacinto Structure-activity relationship of novel phenylacetic CXCR1 inhibitors Bioorg Med Chem Lett 19 2009 4026 4030
142. P. Savi, P. Nurden, A.T. Nurden, S. Levy-Toledano, and J.M. Herbert Clopidogrel: a review of its mechanism of action Platelets 9 1998 251 255
143. S. Schann, S. Mayer, C. Franchet, M. Frauli, E. Steinberg, and M. Thomas Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators J Med Chem 53 2010 8775 8779
144. J.A. Schetz Allosteric modulation of dopamine receptors Mini Rev Med Chem 5 2005 555 561
145. D.J. Scholten, M. Canals, D. Maussang, L. Roumen, M. Smit, and M. Wijtmans Pharmacological modulation of chemokine receptor function Br J Pharmacol 165 2012 1617 1643 (LID)
146. M. Schumacher, and B.S. McEwen Steroid and barbiturate modulation of the GABAa receptor. Possible mechanisms Mol Neurobiol 3 1989 275 304
147. T.W. Schwartz, and B. Holst Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 28 2007 366 373
148. J.J. Sevigny, J.M. Ryan, C.H. van Dyck, Y. Peng, C.R. Lines, and M.L. Nessly Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial Neurology 71 2008 1702 1708
149. 4 mAChR modulates hippocampal synaptic transmission Nat Chem Biol 4 2008 42 50
150. 1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning J Neurosci 29 2009 14271 14286
151. L. Skrabanek, M. Murcia, M. Bouvier, L. Devi, S.R. George, and M.J. Lohse Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base BMC Bioinformatics 8 2007 177
152. N.J. Smith, and G. Milligan Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes Pharmacol Rev 62 2010 701 725
153. N.J. Smith, K.A. Bennett, and G. Milligan When simple agonism is not enough: emerging modalities of GPCR ligands Mol Cell Endocrinol 331 2011 241 247
154. N.J. Smith, R.J. Ward, L.A. Stoddart, B.D. Hudson, E. Kostenis, and T. Ulven Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator Mol Pharmacol 80 2011 163 173
155. A. Soriano, M. Vendrell, S. Gonzalez, J. Mallol, F. Albericio, and M. Royo A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors J Pharmacol Exp Ther 332 2010 876 885
156. J.Y. Springael, E. Urizar, S. Costagliola, G. Vassart, and M. Parmentier Allosteric properties of G protein-coupled receptor oligomers Pharmacol Ther 115 2007 410 418
157. 2 receptors Arch Pharm (Weinheim) 336 2003 385 389
158. L.A. Stoddart, N.J. Smith, and G. Milligan International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions Pharmacol Rev 60 2008 405 417
159. S.K. Sullivan, M.S. Brown, Y. Gao, C.J. Loweth, F.M. Lio, and P.D. Crowe Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists Biochemistry 45 2006 15327 15337
160. A. Talbodec, N. Berkane, V. Blandin, J.P. Breittmayer, E. Ferrari, and C. Frelin Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism Mol Pharmacol 57 2000 797 804
161. L. Teuber, F. Watjens, and L.H. Jensen Ligands for the benzodiazepine binding site - a survey Curr Pharm Des 5 1999 317 343
162. 2 receptors Mol Pharmacol 54 1998 139 145
163. K. Uemura, C.M. Lill, X. Li, J.A. Peters, A. Ivanov, and Z. Fan Allosteric modulation of PS1/gamma-secretase conformation correlates with amyloid beta(42/40) ratio PLoS One 4 2009 e7893
164. S. Urwyler Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol Rev 63 2011 59 126
165. C. Valant, K.J. Gregory, N.E. Hall, P.J. Scammells, M.J. Lew, and P.M. Sexton A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand J Biol Chem 283 2008 29312 29321
166. C. Valant, E. Maillet, J.J. Bourguignon, B. Bucher, V. Utard, and J.L. Galzi Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration J Med Chem 52 2009 5999 6011
167. 1 receptor allosteric modulators Mol Pharmacol 78 2010 444 455
168. 1 receptor J Med Chem 55 2012 2367 2375
169. C. Valant, C.C. Felder, P.M. Sexton, and A. Christopoulos Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects Mol Pharmacol 81 2012 41 52
170. R. van de Lagemaat, C.M. Timmers, J. Kelder, C. van Koppen, S. Mosselman, and R.G. Hanssen Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor Hum Reprod 24 2009 640 648
171. P.A. van der Klein, A.P. Kourounakis, and A.P. IJzerman Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding J Med Chem 42 1999 3629 3635
172. J. Van Durme, F. Horn, S. Costagliola, G. Vriend, and G. Vassart GRIS: glycoprotein-hormone receptor information system Mol Endocrinol 20 2006 2247 2255
173. C.J. van Koppen, and B. Kaiser Regulation of muscarinic acetylcholine receptor signaling Pharmacol Ther 98 2003 197 220
174. C.J. van Koppen, G.J. Zaman, C.M. Timmers, J. Kelder, S. Mosselman, and R. van de Lagemaat A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor Naunyn Schmiedebergs Arch Pharmacol 378 2008 503 514
175. S. Van Poecke, M.O. Barrett, T. Santhosh Kumar, D. Sinnaeve, J.C. Martins, and K.A. Jacobson Synthesis and P2Y(2) receptor agonist activities of uridine 5'-phosphonate analogues Bioorg Med Chem 20 2012 2304 2315
176. N.C. van Straten, G.G. Schoonus-Gerritsma, R.G. van Someren, J. Draaijer, A.E. Adang, and C.M. Timmers The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction Chembiochem 3 2002 1023 1026
177. D. Verzijl, S. Storelli, D.J. Scholten, L. Bosch, T.A. Reinhart, and D.N. Streblow Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors J Pharmacol Exp Ther 325 2008 544 555
178. 5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors Mol Pharmacol 64 2003 21 31
179. I. von Kügelgen, and T.K. Harden Molecular pharmacology, physiology, and structure of the P2Y receptors Adv Pharmacol 61 2011 373 415
180. L. Wang, B. Martin, R. Brenneman, L.M. Luttrell, and S. Maudsley Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders J Pharmacol Exp Ther 331 2009 340 348
181. X. Wang, J.G. Horswill, B.J. Whalley, and G.J. Stephens Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl) phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum Mol Pharmacol 79 2011 758 767
182. J. Wess Allosteric binding sites on muscarinic acetylcholine receptors Mol Pharmacol 68 2005 1506 1509
183. 2 acetylcholine receptor ligands by affinity selection-mass spectrometry J Biomol Screen 11 2006 194 207
184. B. Wu, E.Y. Chien, C.D. Mol, G. Fenalti, W. Liu, and V. Katritch Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
185. S.D. Yanofsky, E.S. Shen, F. Holden, E. Whitehorn, B. Aguilar, and E. Tate Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists J Biol Chem 281 2006 13226 13233